PDF(Pubmed)
Abstract：
UNASSIGNED: Androgenetic alopecia (AGA) is the most common cause of hair loss in men and women, affecting about 30% of men and 15% of women at 30 years and 80% and 48% at 70 years, respectively. This study aims to assess the effectiveness of growth factor cocktail therapy including fibroblast growth factor 9 (FGF9) (Cellcurin) in men and women with AGA.
UNASSIGNED: This is a single-center randomized controlled trial, conducted with 10 men and 10 women with AGA. Eight men participated in the therapeutic group and two men in the control group. Eight women participated in the therapeutic group and two women in the control group. All were classified by sex, age, duration, and degrees of progression of AGA. The study obtained approval from the Research Ethics Committee (REC) of the Federal University of Uberlandia at approval number: 36918620.8.0000.5152. Six microneedling sessions were performed with an electromedical pen with an interval of 15 days between sessions. In the therapeutic group, sterile injectable Cellcurin was used and, in the control group, injectable sterile minoxidil 5 mg/ml 2 ml, both through the drug delivery system. Trichoscopic photos were taken before and after 12 weeks in the frontal and vertex regions. Descriptive statistics were performed using the t-test with the IBM SPSS-25 software.
UNASSIGNED: Men and women showed an expressive and significant increase in the amount of hair per cm2 after Cellcurin therapy, as well as an increase in the amount of terminal hair, vellus hair, sum of the terminal hair diameters, and mean of the terminal hair diameters in both regions, frontal and vertex.
UNASSIGNED: In this study, we demonstrated that the use of Cellcurin in the treatment of AGA in men and women is associated with an increase in the amount of hair per cm2, in the amount of terminal hair per cm2, in the amount of vellus hair per cm2, in the number obtained by the sum of the terminal hair diameters per cm2, as well as an increase in the mean diameter of the terminal hairs.
UNASSIGNED: This is a single-center randomized controlled trial, conducted with 10 men and 10 women with AGA. Eight men participated in the therapeutic group and two men in the control group. Eight women participated in the therapeutic group and two women in the control group. All were classified by sex, age, duration, and degrees of progression of AGA. The study obtained approval from the Research Ethics Committee (REC) of the Federal University of Uberlandia at approval number: 36918620.8.0000.5152. Six microneedling sessions were performed with an electromedical pen with an interval of 15 days between sessions. In the therapeutic group, sterile injectable Cellcurin was used and, in the control group, injectable sterile minoxidil 5 mg/ml 2 ml, both through the drug delivery system. Trichoscopic photos were taken before and after 12 weeks in the frontal and vertex regions. Descriptive statistics were performed using the t-test with the IBM SPSS-25 software.
UNASSIGNED: Men and women showed an expressive and significant increase in the amount of hair per cm2 after Cellcurin therapy, as well as an increase in the amount of terminal hair, vellus hair, sum of the terminal hair diameters, and mean of the terminal hair diameters in both regions, frontal and vertex.
UNASSIGNED: In this study, we demonstrated that the use of Cellcurin in the treatment of AGA in men and women is associated with an increase in the amount of hair per cm2, in the amount of terminal hair per cm2, in the amount of vellus hair per cm2, in the number obtained by the sum of the terminal hair diameters per cm2, as well as an increase in the mean diameter of the terminal hairs.
摘要：
■雄激素性脱发（AGA）是男性和女性脱发的最常见原因，在30岁时影响了大约30％的男性和15％的女性，在70岁时影响了80％和48％，分别。这项研究旨在评估生长因子鸡尾酒疗法（包括成纤维细胞生长因子9（FGF9）（Cellcurin））在AGA男性和女性中的有效性。
■这是一项单中心随机对照试验，与10名男性和10名女性进行了AGA。8名男性参加治疗组，2名男性参加对照组。八名妇女参加了治疗组，两名妇女参加了对照组。都是按性别分类的,年龄,持续时间,以及AGA的进展程度。该研究获得了Uberlandia联邦大学研究伦理委员会（REC）的批准，批准号：36918620.8.0000.5152。使用电医疗笔进行6次微针训练,每次训练之间间隔15天。在治疗组中，使用无菌注射Cellcurin，在对照组中，注射用无菌米诺地尔5毫克/毫升2毫升，都通过给药系统.在12周之前和之后在额叶和顶点区域拍摄了显微镜照片。使用IBMSPSS-25软件的t检验进行描述性统计。
■男性和女性在Cellcurin治疗后表现出每cm2头发数量的表达和显着增加，以及终毛数量的增加，毫毛,末端毛发直径的总和，以及两个区域的终毛直径的平均值，正面和顶点。
■在这项研究中，我们证明，在男性和女性中，使用Cellcurin治疗AGA与每cm2头发量，每cm2终毛量，每cm2毫毛量，每cm2终毛直径之和所获得的数量以及终毛平均直径的增加有关。
■这是一项单中心随机对照试验，与10名男性和10名女性进行了AGA。8名男性参加治疗组，2名男性参加对照组。八名妇女参加了治疗组，两名妇女参加了对照组。都是按性别分类的,年龄,持续时间,以及AGA的进展程度。该研究获得了Uberlandia联邦大学研究伦理委员会（REC）的批准，批准号：36918620.8.0000.5152。使用电医疗笔进行6次微针训练,每次训练之间间隔15天。在治疗组中，使用无菌注射Cellcurin，在对照组中，注射用无菌米诺地尔5毫克/毫升2毫升，都通过给药系统.在12周之前和之后在额叶和顶点区域拍摄了显微镜照片。使用IBMSPSS-25软件的t检验进行描述性统计。
■男性和女性在Cellcurin治疗后表现出每cm2头发数量的表达和显着增加，以及终毛数量的增加，毫毛,末端毛发直径的总和，以及两个区域的终毛直径的平均值，正面和顶点。
■在这项研究中，我们证明，在男性和女性中，使用Cellcurin治疗AGA与每cm2头发量，每cm2终毛量，每cm2毫毛量，每cm2终毛直径之和所获得的数量以及终毛平均直径的增加有关。
